Saturday 17 October 2026
Export KMTS’s income statement to Excel — free account
Kestra Medical Technologies, Ltd.
KMTS Healthcare Medical Instruments & Supplies
Kestra Medical Technologies, Ltd.’s revenue for fiscal 2026 (year ended April 2026) was $95.1 million, up 59.0% from fiscal 2025. In the quarter to July 2026, revenue grew 59.9%, EPS fell 50.0%, free cash flow fell 17.8% and total debt rose 74.7%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
27.24
1.44
−5.02%
Follow KMTS
| Apr '26 | Apr '25 | Apr '24 | |
|---|---|---|---|
Piotroski F-Score |
4 | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 |
Altman Z-Score |
3.87 | 1.36 | — |
P/S ratio |
11.80 | 9.89 | 0.00 |
Altman Z″-Score (non-manufacturers) |
(2.55) | (0.94) | (44.29) |
P/FCF ratio |
0.00 | 0.00 | 0.00 |
P/Operating CF |
(59.97) | (24.59) | (24.13) |
Beneish M-Score |
1.67 | (1.69) | — |
P/B ratio |
4.32 | 2.88 | 0.00 |
Price to Tangible BV |
4.32 | 2.88 | 0.00 |
EV/Sales |
10.19 | 6.60 | 0.00 |
EV/EBITDA |
0.00 | 0.00 | 0.00 |
EV/Operating CF |
(11.86) | (5.09) | (3.73) |
EV/FCF |
(8.29) | (3.91) | (3.04) |
Quick Ratio |
4.19 | 6.47 | 0.31 |
Current Ratio |
4.41 | 6.72 | 0.45 |
Net Debt/EBITDA |
1.24 | 2.03 | (0.47) |
Debt/Assets |
11.90% | 13.90% | 92.57% |
Debt/Equity |
0.16 | 0.20 | (1.32) |
Asset Turnover |
0.29 | 0.35 | 0.00 |
Operating CF/Net income |
0.62 | 0.62 | 0.72 |
Capex/Depreciation |
(3.36) | (2.49) | (1.00) |
Interest Coverage |
(17.86) | (13.75) | (13.65) |
| (56.60%) | 6,352.81% | 0.00% | |
| (40.24%) | (73.83%) | 0.00% | |
ROIC |
(79.54%) | (746.28%) | (2,631.90%) |
Return on Tangible Assets |
(56.96%) | (50.02%) | (1,254.09%) |
Average Days of Receivables |
55.80 | 49.31 | 26.22 |
Research and Development Expense of Revenue |
20.48% | 26.17% | 55.69% |
Selling, General and Administrative Expense of Revenue |
172.53% | 192.15% | 251.44% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
35.37% | 40.58% | 5.35% |
Graham Net Nets |
0.11 | 0.28 | (0.15) |
Graham Number |
0.00 | 0.00 | 0.00 |
Earnings Yield |
(11.68%) | (22.29%) | (22.29%) |
Free Cash Flow Yield |
(10.42%) | (17.06%) | (35.44%) |
Revenue per Share |
1.76 | 2.43 | 1.40 |
Operating CF per Share |
(1.51) | (3.16) | (3.63) |
Capex per Share |
(0.65) | (0.95) | (0.61) |
Free Cash Flow per Share |
(2.16) | (4.10) | (4.25) |
Cash per Share |
3.63 | 9.66 | 0.41 |
Shareholders Equity per Share |
4.79 | 8.36 | (1.62) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 |
Book value per Share |
4.79 | 8.36 | (1.62) |
Free Cash Flow |
(116.94) | (100.92) | (84.46) |
Working Capital |
171.99 | 217.35 | (18.06) |
Capital Expenditures |
(35.24) | (23.31) | (12.23) |
Net Current Asset Value |
123.55 | 164.99 | (63.31) |
EV/EBIT |
0.00 | 0.00 | 0.00 |
Capex to Sales |
0.37 | 0.39 | 0.44 |
Price to Operating Income |
0.00 | 0.00 | 0.00 |
| Other line items | |||
Depreciation/Fixed assets |
0.18 | 0.27 | 0.47 |
Cash ROIC |
(23.45%) | (20.85%) | (456.12%) |
Accounts Receivable Turnover |
8.41 | 11.87 | 0.00 |
Accounts Payable Turnover |
1.81 | 1.49 | 0.00 |
Inventory Turnover |
0.00 | 0.00 | 0.00 |
Average Days of Payables |
215.35 | 245.63 | 317.67 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 |
Average Receivables |
11.31 | 5.04 | — |
Average Payables |
25.63 | 23.93 | — |
Average Assets |
327.10 | 170.85 | — |
Average Common Equity |
232.53 | (1.99) | — |
Columns are period end dates · fundamentals updated 2 Oct 2026